Furthermore, a human therapeutic antibody 264RAD, which binds to αvβ6 and inhibits its function, has been shown to delay tumor growth by preventing TGF-β-mediated activation of CAFs, and by reducing the expression of fibronectin and α-SMA on stromal fibroblasts [110]. This evidence concerns the gene TGFB1 and neoplasm.